The global IV and oral iron drugs market is witnessing strong growth as healthcare providers increasingly adopt advanced iron replacement therapies for chronic anemia management. The market was valued at USD 8.65 billion in 2025 and is projected to grow from USD 9.62 billion in 2026 to USD 22.86 billion by 2034, registering a CAGR of 11.43% during the forecast period.
The rising prevalence of chronic kidney disease (CKD), inflammatory bowel disease, bariatric surgery complications, oncology-induced anemia, and maternal iron deficiency is significantly increasing the demand for effective iron therapies worldwide. Healthcare systems are increasingly prioritizing rapid iron restoration solutions that improve patient outcomes while reducing hospital burden.
Hospitals and specialty infusion centers are rapidly adopting high-dose IV iron formulations such as ferric carboxymaltose and ferric derisomaltose due to their ability to minimize infusion frequency, chair occupancy, and nursing workload. At the same time, oral iron therapies are evolving through liposomal and slow-release technologies that enhance gastrointestinal tolerability and patient compliance.
North America Maintains Dominant Market Position
North America accounted for the largest revenue share of 49.57% in 2025, driven by strong hospital infrastructure, widespread anemia screening programs, and increasing outpatient infusion care adoption.
The United States continues to lead regional growth due to increasing integration of IV iron therapies into patient blood management programs and value-based healthcare systems. Rising adoption of ambulatory infusion centers and growing use of ferric carboxymaltose in oncology supportive care are strengthening market demand across hospitals and outpatient facilities.
Canada is also contributing to regional expansion through government-funded anemia screening initiatives and expanding hematology outreach services in rural healthcare settings.
Asia Pacific Emerges as the Fastest-growing Regional Market
Asia Pacific is projected to register the fastest CAGR of 16.49% during the forecast period. Government-led maternal anemia elimination programs, increasing dialysis populations, and rising post-bariatric surgery cases are supporting substantial market growth across countries such as India, China, Japan, South Korea, and Australia.
Healthcare reforms in China and growing localization of low-cost IV iron manufacturing in India are improving accessibility and affordability of iron therapies. In addition, rising oncology treatment rates and increasing public awareness regarding iron deficiency disorders continue to fuel regional market expansion.
Ferric Carboxymaltose Leads Drug Type Segment
Based on drug type, ferric carboxymaltose accounted for the largest market share of 39.51% in 2025. The formulation is widely preferred because it allows single high-dose administration, reducing the need for repeated hospital visits and improving operational efficiency in infusion centers.
Its increasing use in oncology supportive care, surgical anemia correction, and chronic kidney disease management is supporting segment growth globally.
Meanwhile, the ferric gluconate segment is expected to witness significant growth at a CAGR of 16.11% due to its favorable tolerability profile in hemodialysis-associated anemia treatment programs.
Oral Iron Therapies Gain Momentum
The oral segment is anticipated to grow at a CAGR of 16.08% during the forecast period due to rising demand for affordable and convenient anemia management solutions in homecare and primary healthcare settings.
Advanced oral formulations such as liposomal iron and slow-release preparations are improving patient adherence by minimizing gastrointestinal side effects traditionally associated with oral iron supplementation. Expanding pregnancy supplementation programs and over-the-counter availability in emerging economies are also accelerating demand for oral iron therapies.
Chronic Kidney Disease Remains Leading Application Area
Chronic kidney disease represented the largest application segment, accounting for 31.06% of market revenue in 2025. Patients undergoing long-term dialysis frequently require routine IV iron supplementation alongside erythropoiesis-stimulating agents, making iron therapy a critical component of CKD management.
Additionally, oncology-induced anemia is expected to emerge as one of the fastest-growing application segments due to increasing chemotherapy use and rising emphasis on supportive cancer care globally.
Safety-focused Treatment Protocols Shape Market Trends
Healthcare providers are increasingly implementing phosphate-monitoring protocols during administration of high-dose IV iron therapies, particularly ferric carboxymaltose, due to concerns regarding treatment-induced hypophosphatemia.
Hospitals and infusion centers are integrating electrolyte-monitoring systems and prioritizing safer formulations with lower risks of phosphate depletion. This growing emphasis on safety and treatment optimization is becoming a major competitive factor within the industry.
Expanding Role of Iron Therapy in Heart Failure Management Creates Opportunities
The growing clinical recognition of iron deficiency among heart failure patients is creating new opportunities for iron drug manufacturers. Cardiologists are increasingly incorporating IV iron supplementation into chronic heart failure treatment pathways to improve exercise tolerance, fatigue management, and hospitalization outcomes.
In addition, the rapid expansion of outpatient infusion centers worldwide is improving accessibility to iron therapies while reducing treatment costs compared to traditional hospital-based care models.
Competitive Landscape Intensifies with Innovation and Generic Expansion
The global IV and oral iron drugs market remains moderately consolidated, with multinational pharmaceutical companies competing alongside emerging generic manufacturers.
Leading market participants are focusing on single-dose high-concentration IV formulations, improved safety profiles, and expanded clinical applications across nephrology, oncology, gastroenterology, and cardiology.
Key players operating in the market include:
- CSL
- Daiichi Sankyo
- Covis Pharma
- Akebia Therapeutics
- Shield Therapeutics
- Sanofi
- AbbVie Inc.
- Pfizer Inc.
- Fresenius Medical Care
- Teva Pharmaceutical Industries
- Cipla
- Lupin
- Zydus Lifesciences
- Sun Pharmaceutical Industries
- Viatris
Recent developments indicate growing competitive activity. In November 2025, Shield Therapeutics launched ACCRUFeR (ferric maltol) in Canada through its partnership with Kye Pharmaceuticals following Health Canada approval. Additionally, Viatris received US FDA approval for the first generic iron sucrose injection referencing Venofer for chronic kidney disease-related iron deficiency anemia treatment.
Gain access to expanded insights on competitive strategies, market size, and regional analysis. View our Market Report Overview here:https://straitsresearch.com/report/iv-and-oral-iron-drugs-market
About Straits Research
global market research and consulting company providing comprehensive industry intelligence, business insights, and customized research solutions across healthcare, chemicals, technology, energy, and industrial sectors. The company delivers detailed market forecasts, competitive analysis, strategic consulting, and data-driven insights that support informed business decision-making worldwide.
